Follow the people · Insider
Christopher Van Tuyl
Christopher Van Tuyl files insider transactions with the SEC as a chief legal officer of Immunovant (IMVT). We hold 5 disclosed purchases and sales filed since 18 December 2024, 3 of them in the last 90 days.
- Files forIMVT
- Disclosed buys and sells5 in all, 3 in the last 90 days
- Last disclosure10 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 16 December 2024 — 8 July 2026Chief Legal Officer · Immunovant (IMVT)18 Form 4 lines · source: SEC Form 4
Everything they disclosed
18 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 1,143 shares of ImmunovantSEC Form 410 July 2026Common Stock · traded 8 July 2026 · filed 10 July 2026
- ▼ sold on the open market 63 shares of ImmunovantSEC Form 410 July 2026Common Stock · traded 8 July 2026 · filed 10 July 2026
- exercised options over 17,824 shares of ImmunovantSEC Form 426 June 2026Common Stock · traded 26 June 2026 · filed 26 June 2026
- ▼ sold on the open market 14,982 shares of ImmunovantSEC Form 426 June 2026Common Stock · traded 26 June 2026 · filed 26 June 2026
- ▼ sold on the open market 2,842 shares of ImmunovantSEC Form 426 June 2026Common Stock · traded 26 June 2026 · filed 26 June 2026
- exercised options over 17,824 shares of Immunovant (a derivative holding)SEC Form 426 June 2026Stock Option (right to buy) · traded 26 June 2026 · filed 26 June 2026
- ▼ sold on the open market 2,634 shares of ImmunovantSEC Form 422 June 2026Common Stock · traded 18 June 2026 · filed 22 June 2026
- ▼ sold on the open market 5,165 shares of ImmunovantSEC Form 410 April 2026Common Stock · traded 8 April 2026 · filed 10 April 2026
- was granted 41,343 shares of ImmunovantSEC Form 49 April 2026Common Stock · traded 7 April 2026 · filed 9 April 2026
- was granted 59,820 shares of Immunovant (a derivative holding)SEC Form 49 April 2026Stock Option (right to buy) · traded 7 April 2026 · filed 9 April 2026
- ▼ sold on the open market 2,877 shares of ImmunovantSEC Form 420 March 2026Common Stock · traded 18 March 2026 · filed 20 March 2026
- ▼ sold on the open market 2,877 shares of ImmunovantSEC Form 420 March 2026Common Stock · traded 18 March 2026 · filed 20 March 2026
- ▼ sold on the open market 8,529 shares of ImmunovantSEC Form 419 December 2025Common Stock · traded 18 December 2025 · filed 19 December 2025
- ▼ sold on the open market 2,284 shares of ImmunovantSEC Form 419 December 2025Common Stock · traded 18 December 2025 · filed 19 December 2025
- was granted 71,531 shares of Immunovant (a derivative holding)SEC Form 43 April 2025Stock Option (right to buy) · traded 1 April 2025 · filed 3 April 2025
- was granted 50,787 shares of ImmunovantSEC Form 43 April 2025Common Stock · traded 1 April 2025 · filed 3 April 2025
- was granted 137,446 shares of Immunovant (a derivative holding)SEC Form 418 December 2024Stock Option (right to buy) · traded 16 December 2024 · filed 18 December 2024
- was granted 109,956 shares of ImmunovantSEC Form 418 December 2024Common Stock · traded 16 December 2024 · filed 18 December 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.